ライフサイエンスコーパス: caspase-1 inhibitor

1 SMA in SSc dermal fibroblasts treated with a caspase 1 inhibitor.

2 aride-induced endotoxemia, and injected with caspase 1 inhibitor.

3 inhibited by a caspase-2 inhibitor but not a caspase-1 inhibitor.

4 , TNFalpha, and IL-6) that were blocked by a caspase-1 inhibitor.

5 not inhibited by IL-1 receptor antagonist or caspase-1 inhibitor.

6 Rip2 is a caspase-1 activator, and Cop is a caspase-1 inhibitor.

7 nse to CO, and cell death was inhibited by a caspase-1 inhibitor.

8 ciency, but are unaffected by cathepsin B or caspase-1 inhibitors.

9 pression of siRNA directed against IRF-1 and caspase-1 inhibitors.

10 FN-gamma-induced cell death was inhibited by caspase-1 inhibitors.

11 r antagonist (IL-1RA), and in mice given the caspase 1 inhibitor Ac-YVAD-CMK.

12 ective NLRP3 inhibitor, MCC950; the specific caspase-1 inhibitor Ac-YVAD-cho; and neutralizing anti-I

13 e intracerebroventricularly administered the caspase-1 inhibitor ac-YVAD-CMK (ac-Tyr-Val-Asp-2,6-dime

14 itor Z-DEVD-FMK but were not affected by the caspase-1 inhibitor AC-YVAD-CMK.

15 The tetrapeptide caspase 1 inhibitor (Ac-YVAD-CMK) prevents 3-aminopropan

16 f caspase 3, Ac-DEVD-CHO but not by the ICE (caspase 1) inhibitor, Ac-YVAD-CHO.

17 aspase-3 inhibitor, Ac-DEVD-CHO, but not the caspase-1 inhibitor, Ac-YVAD-CHO, also selectively inhib

18 The pan-caspase inhibitor, ZVAD-fmk, and the caspase-1 inhibitor, Ac-YVAD-cho, both inhibited NO-indu

19 ike activity in Arabidopsis cells, while the caspase-1 inhibitor, Ac-YVAD-CMK, blocked NO-induced cel

20 rther substantiated by the use of a specific caspase-1 inhibitor, Ac-YVAD-CMK.

21 stimulus-coupled response revealed that some caspase-1 inhibitors allow pro-IL-1beta secretion, where

22 as pyroptosis by the protective effect of a caspase 1 inhibitor and a pyroptosis inhibitor.

23 indings identify SHARPIN as a potent in vivo caspase 1 inhibitor and propose the caspase 1-SHARPIN in

24 Caspase 1 inhibitor and the combination of caspase 3 and

25 uced activation of NK cells was prevented by caspase-1 inhibitors and by natural antagonists to IL-1

26 In fact, caspase-1 inhibitors are the first orally active agents

27 Caspase-1 inhibitors blocked all of these responses.

28 caspase 3/7 inhibitor (but not glycine or a caspase 1 inhibitor) blocked morphological damage and DN

29 X-765, an orally active IL-converting enzyme/caspase-1 inhibitor, blocked IL-1beta secretion with equ

30 A selective caspase-1 inhibitor blocks both lipopolysaccharide-induc

31 The caspase-1 inhibitor Boc-D-cmk blocked caspase-1 activity

32 ne release was inhibited by a small molecule caspase-1 inhibitor but not by high levels of exogenous

33 aspase-1 activator Rip2 and reduction of the caspase-1 inhibitor Cop.

34 1a, Il1b, and Nlrp3, and pretreatment with a caspase 1 inhibitor decreased IL-1beta secretion in resp

35 at of cytokine response modifier A, a potent caspase-1 inhibitor from the cowpox virus.

36 )-berkeleyamide A (1), a naturally occurring caspase-1 inhibitor, has been achieved by employing Evan

37 upporting a potential role of the endogenous caspase-1 inhibitor in this chronic inflammatory disease

38 tals were shown to be IL-1-dependent using a caspase-1 inhibitor (inhibits IL-1 maturation) and IL-1R

39 Caspase-1 inhibitor not only attenuated podocyte express

40 Furthermore, the administration of caspase-1 inhibitors or the infusion of bone marrow-deri

41 Inflammasome inhibition with a specific caspase-1 inhibitor, or blocking of IL-1 signaling by IL

42 Tyr-Val-Ala-Asp-chloromethyl ketone, a caspase-1 inhibitor, prevented ATP-induced release of pr

43 vivo proof of concept of the ability of the caspase-1 inhibitor prodrug VX-765 to mitigate alpha-syn

44 Late addition of the caspase-1 inhibitor reversed the losses of plasma membra

45 This cycle can be broken by caspase 1 inhibitors shown to be safe in humans, raising

46 ivation, and support the clinical testing of caspase-1 inhibitors such as VX-765 in autoinflammatory

47 suggest that Flightless-I may be a bona fide caspase-1 inhibitor that acts through a mechanism simila

48 new treatment strategies, such as the use of caspase-1 inhibitors that inhibit pyroptosis, may mainta

49 inflammatory response if a LF was used or a caspase-1 inhibitor was administered during EVLP.

50 ts either saline or a centrally administered caspase-1 inhibitor, which specifically prevents the syn

51 Specific caspase-1 inhibitors would provide a new class of anti-i

52 -)Casp11(-/-) BMDC, WT BMDC treated with the caspase-1 inhibitor YVAD, and BMDC lacking the inflammas

53 tion of IL-1beta production using a specific caspase-1 inhibitor (YVAD-fmk; 100 microM) significantly

54 neral caspase inhibitor Z-VAD-Fmk and by the caspase 1 inhibitor Z-YVAD-Fmk.

55 ant cells was significantly protected by the caspase-1 inhibitor (zVAD-fmk) in a dose-dependent manne